Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

Flagship’s Pioneering Medicines gets cystic fibrosis investment

by Ryan Cross
November 6, 2021 | A version of this story appeared in Volume 99, Issue 41

 

The Cystic Fibrosis Foundation is committing an initial $20 million and up to $110 million to Pioneering Medicines to develop therapies for cystic fibrosis (CF). Pioneering Medicines, an arm of the life sciences venture capital firm Flagship Pioneering, partners with Flagship-founded companies to develop therapies based on their technologies. The gene-editing-therapy firm Tessera Therapeutics, which emerged in 2020, is one of the places Pioneering Medicines will direct the foundation’s investment.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.